The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1357
February 7, 2011
View Complete Issue         Table of Contents 2019 
Pegloticase (Krystexxa) for Treatment of Refractory Gout
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Pegloticase (Krystexxa) for Treatment of Refractory Gout
February 7, 2011 (Issue: 1357)
Pegloticase (Krystexxa – Savient), a PEGylated urate oxidase enzyme, has been approved by the FDA for intravenous (IV) treatment of chronic symptomatic gout in adults who have not responded to maximum doses of a xanthine oxidase inhibitor, such as...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Pegloticase (Krystexxa) for Treatment of Refractory Gout
Article code: 1357b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.